PM
EVFM

Prosight Management’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Prosight Management’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-16,667
Closed -$590K – 60
2020
Q3 		$590K Sell
16,667
-10,852
-39% -$472K 0.28% 42
2020
Q2 		$1.17M Buy
+27,519
New +$1.85M 0.5% 43

Other funds holding EVFM

Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $2.25B AUM 44.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
TWMP
Taylor Wealth Management Partners Boston, Massachusetts $176M AUM 14.65% 1-Year Est. Return

Prosight Management's EVFM Position: Q4 2020 in Review

Prosight Management sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q4 2020, closing a stake of 16,667 shares — an estimated $590K sold.

Prosight Management first reported a position in EVFM in Q2 2020 and held it in 2 quarters. The position peaked at $1.17M in Q2 2020. 93 funds tracked by Wall St. Rank hold EVFM as of Q4 2020.

  • Prosight Management reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Prosight Management sold 16,667 Evofem Biosciences, Inc. Common Stock shares in Q4 2020, an estimated $590K.
  • Prosight Management first reported a position in Evofem Biosciences, Inc. Common Stock in Q2 2020 and held it in 2 quarters.
  • Prosight Management's Evofem Biosciences, Inc. Common Stock position peaked at $1.17M in Q2 2020.
  • 93 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q4 2020.

Based on Prosight Management's 13F filing for Q4 2020, filed 12 Feb 2021.